Why are there more testable diagnostic and therapeutic agents than available patients for clinical trials?

In the context of translational medicine, the disparity between the high number of testable diagnostic and therapeutic agents and the limited number of available patients for clinical trials arises from several critical factors:

• Technological Proliferation: Modern biotechnology has significantly increased the volume of new diagnostic and therapeutic tools that require validation in human subjects before they can be incorporated into medical practice.1
• Limited Predictive Accuracy: Current preclinical models often lack the accuracy to reliably screen candidate products. This results in a high volume of agents moving toward clinical testing without sufficient assurance of their success in humans, further straining the limited pool of available patients.1
• Complexity of Evaluation: Newer agents, such as those involving genetic modification or cellular substances, act through complex, often poorly understood mechanisms. This complexity makes standardizing validation strategies difficult and increases the burden of clinical testing.1
• Resource Constraints: The astronomical costs associated with clinical trials and the logistical challenges of recruiting participants for specialized studies exacerbate the competition for patient enrollment.1